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Available online 10 September 2011Background: One of the most frequently investigated hypotheses of the pathophysiology
underlying Seasonal Affective Disorder (SAD) is a disturbance of circadian rhythms. Since
the circadian system as well as other non-visual effects is especially sensitive to blue light,
a new light therapy device with blue enriched polychromatic light was tested for its efficacy
to treat SAD.
Methods:Within one winter 52 patients were treated in one of three conditions: 30 min full
spectrum light (9000 lx, 5000 K), 30 min blue-enriched light (9000 lx, 17,000 K), or 20 min
blue-enriched light. The study lasted 22 days with 10 days of morning-light treatment on
weekdays during the first 2 weeks.
Results: Depressive symptoms (SIGH SAD) diminished over the 3-week period in all condi-
tions, with no significant differences between conditions. The percentage responders were
high, differing from 75%, 59% and 71% for the standard-LT, 30 min blue-enriched-LT, and
20 min blue-enriched-LT, respectively.
Conclusion: The lack of superiority of high intensity blue-enriched light over standard bright
light treatment does not clearly support nor rule out the possibility of an important role for
the circadian system or the blue sensitive non-visual image forming system in general, in the
pathophysiology of SAD. The lack of a difference between conditions may also be the result
of a saturated response to the high light intensities used. Recent data indeed suggest that
low intensity blue-enriched light may be as effective as standard bright light treatment.
The possibility of improving light therapy for SAD patients by applying light of shorter dura-
tion or at lower light intensities is highly relevant for optimizing treatment and will help to
clarify the role of the circadian system and/or the non-image forming photoreceptors in SAD
pathophysiology.
Clinical trial: https://register.clinicaltrials.gov: NCT01048294.
© 2011 Elsevier B.V. Open access under the Elsevier OA license.Keywords:
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Seasonal Affective Disorder (SAD), wintertype, and suc-
cessful exposure to bright artificial light treatment were for
the first time described in a classic paper by Rosenthal et al.gen, Centre for Life
3, 9700 CC Groningen
632148.
dijn).
lsevier OA license.,(1984). More studies of successful light treatment in SAD
followed (Golden et al., 2005; Meesters et al., 1995; Terman
et al., 1989; Terman and Terman, 2005; Thompson, 2001).
Full-spectrum, white fluorescent light was first used as light
source mimicking the distribution and range of visible and
ultraviolet light in the sky (Partonen, 2001).
So far, the pathophysiology of SAD and the working
mechanism of light in treating SAD have remained unclear.
One of the most frequently investigated hypotheses is based
on a disturbance of the circadian system. It was hypothesized
that SAD sufferers in their depressed state had a delay in
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reflecting a late phase of the endogenous circadian oscillator
(Lewy et al., 1987, 1988). In several studies it was argued
that light administered at certain times of day corrected
this disturbed phase and thereby improved mood (Lewy
et al., 1988; Terman et al., 2001). Whether this is in fact the
mechanism behind light treatment in SAD remains unclear
(Koorengevel et al., 2003; Meesters, et al., 1993; Wirz-Justice
et al., 1993), although the success of morning light treatment
in particular is beyond doubt (Lewy et al., 1998; Terman et al.,
2001).
Discussing the possible mechanisms underlying the posi-
tive effect of light therapy in sleep and mood disorders is im-
portant, not only to improve therapeutic strategies and to
gain insight in the etiology of the disorders, but also to increase
our knowledge of the functional role of the biological clock and
the non-image forming system in general in everyday life. The
purpose of the present study is to test a new therapeutic light
source for the treatment of SAD, whose development is based
on our current knowledge on the spectral sensitivity of the
non-visual image forming photosensory system.
The discovery of a new photoreceptor besides the hitherto
well-known rods and cones in the retina of mammalian eyes
(Berson et al., 2002; Hattar et al., 2002) is an important step
forward in our understanding of the non-image forming effects
of light. These light sensitive retinal ganglion cells play a major
role in the transport of light information to the biological
clock and other brain areas (Berson et al., 2002; Dacey et al.,
2005; Drouyer et al., 2007). Melanopsin is the photosensitive
pigment in the retinal ganglion cells with a peak sensitivity of
approximately 480 nm (blue light). It was proved to be present
in both animal (Hattar et al., 2002; Provencio et al., 1998) and
human retinas (Dacey et al., 2005; Dkhissi-Benyahya et al.,
2006; Provencio et al., 2000) and it serves a function as non-
image forming photic pigment.
Several studies showed that the human circadian system
is particularly sensitive to the short wavelength portion of
the light spectrum. Brainard et al. (2001) and Thapan et al.
(2001) showed that melatonin suppression is largest during
exposure to a narrow band light stimulus between 460–
480 nm. Exposure to 6.5 h of monochromatic light of 460 nm
induced a circadian phase delay twice as large as exposure to
monochromatic light of 555 nm with equal photon density
(Lockley et al., 2003). The authors of this study conclude
that the peak sensitivity of the human circadian pacemaker
is shifted more to the blue part of the spectrum relative to
the peak sensitivity of the three-cone visual photopic system,
which peaks around 555 nm.
Wright and Lack (2001) and Wright et al. (2004) com-
pared the effects of red light (660 nm), amber light
(595 nm), green light (525 nm), blue/green light (497 nm)
and blue light (470 nm) on their capacity to phase shift
the salivary melatonin rhythm. Light with shorter wave-
lengths turned out to be more effective than light with
longer wavelengths in suppressing nocturnal melatonin con-
centration and phase-delaying/advancing the melatonin
rhythm. The two longer wavelengths did not produce any
significant phase advances, the shorter wavelength showed
melatonin onset advances ranging from 40–65 min. Warman
et al. (2003) compared the phase advancing properties of
a full-spectrum light pulse with a light pulse without longwavelengths. The white light pulse contained 185-fold more
photons than the short wavelengths light. Exposure to the
filtered morning light pulse, containing mainly short wave-
lengths, induced larger phase advances of the offset of the
melatonin rhythm.
From these studies using narrow bandwidth or filtered light
pulses, it is clear that the human circadian system is more sensi-
tive to light with short wavelengths than to light with longer
wavelengths. Also other non-image forming responses to
light, such as an increased alertness, thermoregulation and
heart rate, show a high sensitivity to short-wavelength
light (Cajochen et al., 2005) and recently it was shown that
emotional processes in the brain are modulated by exposure to
blue light (Vandewalle et al., 2010). Although the discovery of
the retinal ganglion cells containing melanopsin has been
a great impulse for new studies on the effects of narrow
band shortwavelength light (blue light), the classical visual pho-
toreceptors should not be neglected as far as their influence on
the circadian system are concerned (Brainard and Hanifin,
2005; Drouyer et al., 2007; Hanifin et al., 2006). In two studies
it was postulated that melanopsin itself has dual photosensory
mechanisms and that longwavelengthsmay restoremelanopsin
photosensitivity (Melyan et al., 2005; Mure et al., 2007). In a
recent study, Gooley et al. (2010) showed that the classical pho-
toreceptor system clearly plays a role in non-image forming
responses especially at the beginning of the light pulse.
So far, only a few studies using blue light in the treatment
of SAD sufferers are known. These types of studies will in-
crease our knowledge on the pathology and may improve our
therapeutic tools to treat depression. In one study, a portable
LED device was used. The spectral composition of this lamp
shows peaks at 464 nm and 564 nm. Within the range of
400–700 nm about 48% of the energy is emitted in the range
of 420 nm–508 nm, and 37% in the range of 512 nm–616 nm.
In a relatively small controlled trial the effects of exposure to
this light source were compared to those of an inactivated ion
generator (placebo). The effects in the light condition turned
out to be superior to those in the placebo condition (Desan
et al., 2007), but it is unclear to what extent the spectral char-
acteristics of the light in this study are responsible for the im-
provements observed, since no light was given in the control
condition. In another study, the effects of exposure to the
light of narrow-band light-emitting diodes (LED's) were inves-
tigated. Blue light (468 nm) was superior in treating SAD suf-
ferers when compared to dim red light (654 nm) (Glickman
et al., 2006). Although the short wavelength light was superior
to the longer wavelength in this study, SAD sufferers still
showed some improvement after they had been exposed to
the red light. No comparison was made with standard light
treatment (full spectrum white light without UV). This last
comparison was recently made in a study of Anderson et al.
(2009). They found that blue monochromatic light in a lower
photopic intensity than white light, but with the same amount
of blue light, is similarly effective in treatment of SAD.
A new development in the field of light sources based
on the current scientific knowledge is to produce broad spec-
trum white light sources obtaining more photons in the
short wavelength region. In chronobiological terms this
light is hypothesized to be more potent in inducing non-
visual effects. Recently our group published a small study
to test the hypothesis that a low intensity of blue enriched
Fig. 1. Spectral power distributions of the lamps used in the standard Energy
Light® (5000 K) and the high color prototype Energy Light® (17,000 K).
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10,000 lx; Meesters et al., 2011) and concluded that both
are effective treatments.
In the present study the same fluorescent tubes that emit a
high portion of short wavelength light on top of the normal
wavelengths were tested for their superiority in treating SAD
in three relatively large groups. In a carefully controlled single
blind setup, blue-enriched light (color temperature 17,000 K)
was compared to standard light treatment (5000 K) in SAD
patients. We hypothesized that blue-enriched light improves
the therapeutic effects of light treatment leading to a higher
response or the same response in a shorter time compared
to standard light treatment.
2. Methods
2.1. Subjects
In the winter of 2005/2006 (between October 1st, and
February 10th) all patients who entered the SAD outpatient
clinic of the University Medical Center Groningen, The
Netherlands, to receive light therapy were asked to partici-
pate. Approximately 200 patients known for winter depres-
sion are followed each year during autumn and winter and
are completing the Beck Depression Inventory for Depres-
sion (BDI-II-NL, Beck et al., 2002) weekly, starting in the
first week of September. As soon as the score is equal or
higher than 15 the patient is invited to visit the clinic for
light therapy. All patients that reached this score were asked
to participate in the research project. If they considered partic-
ipation they received written information, and were invited
for an intake interview. Newpatients referred to the outpatient
clinic were diagnosed by an experienced clinical psychologist
and if suffering from winter depression they were informed
about the research project. After they signed the informed
consent they were scheduled for the intake interview;
52 subjects (40f, 12 m; 38.8y, sd 11.6) were included in the
study, of whom 28 patients had received light therapy in previ-
ous years (“known” subjects) and 24 patients received light
therapy for the first time (“new subjects”). Age was not signif-
icantly different between the two groups (“known” subjects:
age 40.0y±sem 2.2, range 22.2–61.4y; new subjects: age
37.3±sem 2.3, range: 20.2–55.9y, F(1,50)=0.75, ns).
The intake interview consisted of two semi-structured
standardized interviews, the Mini-International Neuropsy-
chiatric Interview (M.I.N.I., Sheehan et al., 1998) and the
Structured Interview Guide for the Hamilton Depression
Rating Scale-Seasonal affective disorder 24 items version.
(SIGH-SAD, Williams et al., 1994). If patients met the criteria
of a major depressive disorder with a seasonal pattern,
wintertype, according to the DSM-IV-TR (APA, 1994), and
scored on the 24 items SIGH-SAD at least 18 they
were included and assigned to one of the three conditions.
No atypical score threshold was used in selection of the
subjects. Researchers and interviewers were completely
blind for the condition during the study period of 5.5 months.
Also patients were not informed on their assignment, al-
though subjects who received 20 min of treatment could
know in what condition they were in.
The protocol was approved by the Medical Ethical
Committee of the University Medical Center Groningen.2.2. Light therapy
Light treatment consisted of 2 weeks standard light thera-
py (Standard-LT, 5000 K) with the Energy Light® (Philips
Consumer Lifestyle, Drachten, The Netherlands) or 2 weeks
high color light therapy with a specially modified Energy-
Light®, equipped with blue-enriched white lamps of
17,000 K that emit a higher proportion of short wavelengths
(Blue-enriched-LT, 17,000 K). Fig. 1 shows the comparison
of the spectral power distributions of the standard and
blue-enriched lamps. Subjects came to the department on
10 workdays (days 4–8 and days 11–15 in the protocol) and
obtained either 30 min Standard-LT, 30 min Blue-enriched-LT
or 20 min Blue-enriched-LT between 7:45 and 8:45 a.m.
Intensity of the light measured at eye level in the direction
of gaze was between 9000 and 10,000 lx for both conditions
(Standard-LT: 3070 μW/cm2, 8.4*1015 photons; Blue-enriched-
LT: 3810 μW/cm2, 10.4*1015 photons).
2.3. Assessment
If the patients met the inclusion criteria, they were asked
to complete the BDI-II-NL, (Beck et al., 2002), and a specific
expectation questionnaire aimed to evaluate the expectation
of the effects of light therapy. This last questionnaire rated
on a 5 point scale for both the Standard-LT and the Blue-
enriched-LT whether subjects expected to benefit from the
therapy, whether they thought it was a logical treatment,
and whether they thought they would recommend this ther-
apy to a friend.
Each condition started at day 1 (Friday) with a baseline
measurement, conducting a SIGH SAD interview in addition
to the self rating questionnaire BDI-II-NL. Subjects who did
not meet the criterion for depression (SIGH-SAD ≥18) at
day 1 were excluded. The SIGH-SAD and the BDI-II-NL were
repeated on day 8 (shortly after the 5th light session), on
day 15 (shortly after the 10th light session) and on day 22
(1 week after ending the light treatment). On day 22 an eval-
uation questionnaire was added to check the outcome of the
expectations. Starting at day 1, subjects rated their mood on
a daily schedule in the morning at least 30 min after waking
up, preferably at 8.00 a.m., using the Adjective Mood Scale
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or restrictions of for instance sleep schedule were given. All
subjects in the three groups continued their normal daily
life, except for their visits to the lab to obtain light treatment.
2.4. Statistics
The proportional improvement scores and effect sizes
(Cohen, 1988) were calculated for each condition. The results
of the two conditions were then compared by means of
ANOVA with repeated measures.
3. Results
3.1. SIGH SAD
Subjects were randomly assigned to the 3 different condi-
tions, taking care of dividing gender and age evenly over
the groups. No significant differences between conditions
(Standard-LT, Blue-enriched-LT30, Blue-enriched-LT20) in
both gender ratio (f/m ratio 14/3, 14/4, and 12/5; Χ2=0.67,
ns), nor in average age (mean±s.e.m.: 39.2±3.4; 37.9±
2.6; 39.3±2.4y; F(2,49)=0.80, ns), nor in severity of depres-
sion as measured with the SIGH SAD (24 items, F(2,49)=
0.60, ns), the HRSD (17 items, F(2,49)=0.34, ns), the atypical
Symptoms (7 items, F(2,49)=1.94, ns), nor with the BDI
(F(2,49)=0.57, ns) at day 1 between the groups in the
different conditions were observed (see Table 1).
The depressive complaints decreased during the 3-weeks
period in all conditions (Fig. 2 and Table 1, SIGH SAD 24Table 1
Average depression scores (± SD) during each 3-week period; Cohens d effect size
therapy) and from day 1 to day 22 (1 week after last light treatment), as rated by the
for seasonal symptoms SIGH SAD (24 items), and the atypical symptoms separately
condition. Within subjects Contrast: *=p≤0.001; #=p≤0.01 compared to day 1.
Day 1
(SD)
Day 8
(SD)
Day 15
(SD)
Da
(SD
SIGH-SAD Standard-LT 27.2 15.2* 8.9* 6
(n=17) (5.6) (8.5) (9.0) (7
Blue-enriched-LT30 27.2 17.2* 11.5* 10
(n=18) (5.7) (7.6) (8.7) (9
Blue-enriched-LT20 25.3 17.3* 10.5* 7
(n=17) (6.1) (7.8) (9.4) (7
HRSD Standard-LT 14.2 8.6# 5.8* 3
(n=17) (5.8) (5.8) (6.2) (4
Blue-enriched-LT30 15.7 10.1* 7.1* 6
(n=18) (5.2) (5.1) (5.5) (6
Blue-enriched-LT20 14.9 10.5# 6.5* 4
(n=17) (4.9) (5.5) (5.6) (4
ATYP Standard-LT 12.9 6.6* 3.1* 2
(n=17) (4.2) (4.6) (3.3) (3
Blue-enriched-LT30 11.4 7.0# 4.4* 3
(n=18) (3.7) (4.4) (3.7) (3
Blue-enriched-LT20 10.4 6.8* 4.0* 2
(n=17) (3.3) (4.0 (4.0) (3
BDI-II Standard-LT 24.6 14.5* 10.5* 6
(n=17) (7.7) (6.4) (11.3) (8
Blue-enriched-LT30 23.4 14.1* 11.3* 12
(n=18) (8.6) (7.5) (9.1) (10
Blue-enriched-LT20 21.6 15.2# 8.7* 6
(n=17) (8.5) (9.7) (7.5) (7items, main effect “time” F(3,47)=66.6, pb0.001), with
no significant differences between conditions (main effect
“condition” F(2,49)=0.73, ns) nor over time between condi-
tions (interaction effect “time*condition” F(6,96)=0.56, ns).
The same pattern was found if the SIGH SAD was separated in
“typical symptoms” (17 item Hamilton rating, Table 1, main
effect “time” F(3,47)=45.1, pb0.001; main effect “condi-
tion” F(2,49)=0.96, ns; interaction effect “time*condition”
F(6,96)=0.3, ns) and “atypical items” (7 atypical items,
Table 1, main effect “time” F(3,47)=41.2, pb0.001; main
effect “condition” F(2,49)=0.30, ns; interaction effect
“time*condition” F(6,96)=0.67, ns). Post-hoc analysis for
all three outcome variables (SIGH SAD24, HAM17 and atyp-
ical symptoms7) revealed that a significant improvement
was observed after the first week (day 8) compared to base-
line (day 1) for all three treatments (post hoc pb0.05). An
even further significant improvement (post hoc pb0.05)
after the second week of treatment (day 15) compared
to after the first week (day 8) was found for all treatments
in all variables, except for the HAM17 in the Standard-LT
condition (p=0.13). No significant changes in severity of
symptoms were observed 1 week after the last day of light
treatment (day 22) for all variables in all conditions compared
to the day immediately after light therapy (day 15), although
the continuing reduction in depression scores in the 20 min
Blue-enriched-LT condition almost reached significance (SIGH
SAD F(1,16)=3.9 p=0.06; HAM17 F(1,16)=4.3, p=0.06).
The percentage response at day 22 (defined as the percent-
age change in SIGH SAD (24 items) rating relative to day 1)
is not significantly different between conditions (Table 1); onand percentage response from day 1 to day 15 (immediately after last light
Hamilton rating scale for Depression (HRSD, 17 items) and the scale adapted
(7 items), including the score on the Beck Depression Inventory-II for each
Day 1–15 Day 1–22
y 22
)
% Response
(sem)
Cohen's d,
(Effect size)
% Response
(sem)
Cohen's d,
(Effect size)
.5* 66.0 2.44 74.7 3.18
.3) (8.3) 0.77 (6.7) 0.85
.6* 58.0 2.13 58.8 2.12
.5) (7.6) 0.73 (9.0) 0.73
.2* 58.0 1.87 71.0 2.71
.2) (7.8) 0.68 (6.6) 0.80
.9* 55.4 1.40 72.9 1.97
.6) (12.0) 0.57 (6.9) 0.70
.8* 54.8 1.61 50.4 1.57
.1) (8.9) 0.63 (12.0) 0.62
.4* 55.0 1.60 71.2 2.23
.5) (7.7) 0.62 (7.3) 0.74
.7* 69.9 2.59 75.1 2.67
.4) (8.5) 0.79 (7.9) 0.80
.8* 58.4 1.89 63.8 2.00
.9) (8.4) 0.69 (8.2) 0.71
.8* 59.0 1.75 70.4 2.30
.3) (9.1) 0.66 (7.8) 0.76
.5* 54.5 1.46 70.5 2.26
.3) (10.4) 0.59 (9.0) 0.75
.0# 52.8 1.37 44.1 1.17
.7) (9.2) 0.56 (13.7) 0.51
.4* 60.1 1.61 70.3 1.92
.3) (7.9) 0.63 (7.7) 0.69
Fig. 2. Course of SIGH SAD rating (24 items) measured on day 1 (=baseline),
day 8 (=5th day of light treatment), day 15 (=10th day of light treatment)
and day 22 (after one week withdrawal) in the three groups. A significant
effect of time, but no significant difference between treatments was observed.
Fig. 3. Course of SIGH SAD ratings on day 1 (=baseline), day 8 (=5th day
of light treatment), day 15 (=10th day of light treatment) and day 22
(after one week withdrawal) for the group of patients who were treated
with light therapy in previous years (“known”), and for the group of “new”
winter depressed patients who received light therapy for the first time.
A significant time*group interaction was found (pb0.05) and a significant
difference at day 22. No significant interaction effect was found between
treatments, and therefore they were combined.
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the 30 min Blue-enriched-LT up to 71.0% in the 20 min Blue-
enriched-LT condition and 74.7% in the standard-LT condition
(F(2,49)=1.2, ns). The average response at day 15, the
last day of the light therapy, is lower but also not significantly
different between conditions; it differs from 58.0% in both
Blue-enriched-LT conditions up to 66.0% in the standard-LT
condition (F(2,49)=0.3, ns). Although not statistically signifi-
cant from the other treatments, the most striking difference
is the relatively low response at day 22 to the 30 min Blue-
enriched-LT (58.8% compared to 71.0% and 74.7% in the 20 min
Blue-enriched-LT and standard-LT condition respectively).
The percentage responders at day 22 (defined as a reduc-
tion in symptoms of ≥50%) to the different treatments,
was higher than 70% in all conditions, with no significant dif-
ferences between conditions (76%, 72% and 71% for standard-
LT, blue-enriched-LT30 and blue-enriched-LT20 respectively,
Χ2=0.19, ns). The fraction of patients who recovered, (reduc-
tion in symptoms of≥50% and≤8 on day 22), slightly differed
from 50% in Blue-enriched-LT30 to 65% in Blue-enriched-LT20
and 76% in Standard-LT, but also this difference was not signif-
icant (Χ2=5.35, ns).
Part of the subjects included were already known for
winter depression and received successful light therapy in
previous winters (n=28), others were diagnosed during
the current year and received light therapy for the first
time (n=24). Obviously a difference in response percentage
may be expected between these groups, because the “known”
patients responded favorably to light therapy already in previ-
ous years, and it may be expected that a certain percentage
of the “new” patients will be non-responders.
A statistical test with as an additional “between” factor –
patient characteristic – (“known” or “new”), revealed that
there is a significant interaction effect between the course of
the SIGH SAD rating over time and the factor patient charac-
teristic (F(3,44)=3.9, pb0.05). This means that the pattern
of the SIGH SAD ratings over time between “known” and
“new” subjects differed significantly. No interaction effect
with treatment condition was found (F(6,90)=0.7, ns),
meaning that this difference in response between “known”
and “new” subjects was not related to the type of the lighttreatment. Fig. 3 shows the course of SIGH SAD in the
two groups, with treatment conditions combined. At day 15,
no significant difference exists between “known” and “new”
patients. The average reduction in depressive symptoms
at day 15 is 55.7% (sem 6.2) in “known” and 66.4% (sem 6.5)
in “new” patients (t-test, n.s.). One week after the light treat-
ment the “new” subjects on average became a little bit worse
(−8.6% sem 6.8), while the “known” subjects continued
to show a slight improvement (21.0% sem 5.2) compared to
day 15 (t-test, p≤0.001).
As a consequence, the average response in SIGH SAD rating
from day 1 to day 22 indeed shows a significant difference be-
tween “known” patients treated before, and “new” patients
treated for the first time: “known” patients show a reduction
in depressive symptoms of 76.7%±4.6, “new” patients a re-
duction of on average 57.8%±7.4 (F(1.50)=5.0, pb0.05).
From the “known” patients 82% are defined as responders,
79% as recovered, according to the criteria defined before. In
the “new” patient group these values are 63% and 46% respec-
tively. Since the two groups did not differ according to age this
cannot be the explanation for the observed differences.
Unfortunately, due to randomization, the “known” and
“new” subjects were not evenly distributed over the different
treatment conditions. The ratio of “known”/”new” patients
for the different treatment conditions is: Standard-LT 12/5;
Blue-enriched-LT30 6/12; Blue-enriched-LT20 10/7 (Χ2=5.13,
p=0.08). Obviously especially in the Blue-enriched-LT30
condition, the “new” subjects were overrepresented. This
may explain the somewhat lower, although not significantly
so, response rates and higher SIGH SAD scores on day 22 in
the Blue-enriched-LT30 condition (see Table 1 and Fig. 2).
3.2. Daily mood ratings, speed of the therapeutic effect
It could be hypothesized that the final result of the differ-
ent treatments is similar, but that the speed with which
this effect is reached differs between conditions. To test this
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the morning during all 22 days. In two subjects daily ratings
were missing for one week (once in Standard-LT and once
in the Blue-enriched-LT30 condition). These subjects were
excluded for the present analysis. Fig. 4 shows the course
of depressive mood (AMS) in the responders to the three
different light treatment conditions (12 in each in condition).
The severity of depressive mood significantly reduces over
time (F(21,13)=5.2, pb0.005), with no significant overall
differences between conditions (F(42,28)=0.93, ns). To ana-
lyze the speed of the response, the moment at which an indi-
vidual's smoothed curve (3 days running average) crossed the
midpoint value of the three highest and the three lowest AMS
scores of that individual was calculated (arrows in Fig. 4). In
the Standard-LT condition this point was reached on average
at day 9.3 (sem 1.1), in the Blue-enriched-LT30 at day 9.2
(sem 1.0), and in the Blue-enriched-LT20 condition at
day 11.0 (sem 0.9). Anova revealed no significant differences
between conditions in the speed of the effect in responders
(F(2,33)=0.96, ns).
3.3. Expectations
On average there were no significant differences in expec-
tations between groups to 4 out of the 6 different questions
(ANOVA): 1) do you think you would benefit from
standard-LT (F(2,47)=0.64, ns), 2) do you think standard-
LT is a logical treatment choice (F(2,47)=0.98, ns), 3)
would you advise standard-LT to a friend (F(2,47)=1.34,
ns), 4) do you think Blue-enriched-LT is a logical treatment
choice (F(2,47)=1.61, ns). The only significant differences
were a somewhat more negative expectation of the Blue-
enriched-LT20 group to both the question whether they
thought they would benefit from the treatment with
more blue light (2.6±0.2) compared to the Standard-LT
group (3.3±0.2, pb0.01; Post Hoc ANOVA) and the Blue-
enriched-LT30 (3.1±0.1, pb0.05) and whether they would ad-
vise it to a friend (2.5±0.2 in Blue-enriched-LT20) compared
to both Standard-LT (3.2±0.2, pb0.01) and Blue-enriched-
LT30 (3.4±0.1, pb0.001).Fig. 4. A) Course of average daily mood ratings (depressive mood with Adjective Moo
crossing the average mood rating over the whole period for each condition as an indi
treatment. B) Average mood rating (depressive mood with Adjective Mood Scale o3.4. Age
To test whether the response to the different treatments
related to age, the subjects were split in three equally large
percentiles. Cut-off points for age were set at lower than
or equal to 29.8y (17 subjects), between 29.8y and 45.3y
(18 subjects), and higher than 45.3y (17 subjects). Overall
there was a significant effect in response of age according
to the SIGH SAD (F(2,49)=4.00, pb0.05). Post hoc analysis
revealed that the youngest group had on average a worse re-
sponse (52%±10) than the middle group (80%±5, pb0.01).
Both groups showed no significant difference from the oldest
group (71%±6, ns). No significant interaction effect was
found between age and condition (F(4,43)=0.18, ns). Re-
sponse percentage in young, middle and oldest group to the
different light conditions were respectively Standard-LT:
60%, 83%, 82%, Blue-enriched-LT30: 41%, 78%, 82%, and Blue-
enriched-LT20 : 55%, 80%, 74%.
4. Discussion
The therapeutic responses after exposure to blue enriched
light in SAD patients were not higher compared to exposure
to standard light treatment, but treatment effect was high
in all three cases. The effect of blue enriched light during ses-
sions with a duration of 20 min did not differ from sessions
with a duration of 30 min exposure to either standard light
treatment or blue enriched light treatment, neither in final
success nor in speed of the effect. The conclusion is based
on the effects measured on day 22, one week after the last
treatment day as performed in our previous studies, although
the same pattern is observed on day 15 immediately after
treatment. Success percentages are however higher one
week after ending of the treatment compared to immediately
after the last light session. Assessing the treatment effect one
week later excludes the possibility that the effect is due to an
acute effect of light. Meesters (1995) previously discussed
that improvement ratings depend on the timing of assess-
ment, showing that effects 10 days after ending of the treat-
ment seemed more pronounced compared to immediatelyd Scale of Von Zerssen). Arrows indicate the day at which depressive mood is
cation of response speed. Gray bars indicate the 2 times 5 days timing of light
f Von Zerssen) over 22 days±SD.
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light observed immediately after therapy were gone 10 days
after the end of the treatment while the effects of morning
light became even more pronounced (Richter et al., 1992)
supports the idea that assessment of the effect a few days
after the last light session is better to compare the effective-
ness of different therapy strategies.
Monochromatic blue light was previously found to be su-
perior compared to monochromatic red light in the treat-
ment of SAD sufferers (Glickman et al., 2006; Strong et al.,
2009). We used polychromatic light with all wavelengths
of the visible light spectrum available and with the blue
part extended compared to the standard light treatment.
The enrichment of the blue part of the spectrum did
not lead to a higher response. It is remarkable that the short
sessions of 20 min blue-enriched light exposure have the
same effect as the longer sessions. An explanation might be
that the maximal response to light treatment is already
reached very quickly and that saturation played a role in
the present study. Support for the finding that the blue part
of the spectrum is important for the therapeutic effect
comes from a study by Anderson et al. (2009). They reported
that blue monochromatic light in a lower photopic intensity
than white light, but with the same amount of blue light, is
similarly effective in treatment of SAD. Much lower intensi-
ties of either blue light alone, a combination of green light
and blue light (Gooley et al., 2010) or blue-enriched light
could therefore be as effective as the high intensities used
in the standard bright light treatment devices. If using
(more) blue light in treatment devices, the potential risks
of retinal damage due to blue light hazard should not be for-
gotten. Although the devices used in the current study emit
blue light intensities far below the international standards
for blue light hazard (CIE, 2002), such risks are cumulative
over years, not immediate. Recently our group performed
an extra study, similar to the current one, to test the hypoth-
esis that a low intensity of blue enriched light is as effective
as standard LT (Meesters et al., 2011). Taking into account
the small number of subjects (n=11 in two groups) it was
shown that there was no significant difference in the antide-
pressive effect, nor on sleep quality or activation/deactivation
parameters, of a daily 30-min blue enriched LT of 750 lx as
compared to a daily 30-min standard-LT of 10,000 lx, both
being effective treatments. In the present study effects of the
three light conditions on sleep have not been analyzed, but
since no differential effects of the light therapy treatments on
mood have been found either, it is not very likely that differen-
tial effects on sleep could have played an important role.
An alternative explanation for the lack of an effect of blue-
enriched light being better than standard light is the possibil-
ity that the blue wavelengths are not necessary for the ther-
apeutic effect in treating SAD. This seems in contradiction to
the findings that blue light plays a clear role in the working
mechanism of the biological clock and in non-image forming
effects in general, even in processes involved in emotion in
certain brain areas (Vandewalle et al., 2010). The role of the
biological clock in the etiology of SAD is however not fully
established (Koorengevel et al., 2003; Meesters, et al., 1993;
Wirz-Justice et al., 1993). Support for the postulated superi-
ority of blue-enriched light treatment and possible involve-
ment of the non-visual image forming system comes fromthe recent finding of a missense variant of the melanopsin
gene found in some SAD patients (Roecklein et al., 2009). Al-
though these data should first be replicated and the functional
consequence of the mutation is difficult to predict, this could
hypothetically indicate deficits in the non-image forming
light input pathway resulting in higher blue light intensities
needed for normal mood patterns in winter months. A
defect in retinal sensitivity to light has been hypothesized to
underlie the occurrence of SAD (Beersma, 1990; Remé et al.,
1990), and recently a study using the electroretinogram tech-
nique showed altered responses of both rods and cones in
the retinas of depressed SAD patients compared to healthy
controls (Lavoie et al., 2009). The anomalies in SAD patients
were normalized after 4 weeks of light therapy. More precise
techniques and combinations of techniques are needed
to investigate possible anomalies in melanopsin containing
photoreceptors in SAD patients.
Finally, the similar responses to the different treatments
could be interpreted as placebo effects only. Actually it is not
really possible to perform a good placebo study for light thera-
py; there will always be a visible difference between the actual
treatment and the placebo condition. The few studies testing
light therapy in winter depressives using a reasonable placebo
condition revealed placebo effects that differed between 21%
and 40% (Eastman et al., 1998; Koorengevel et al., 2001; Levitt
et al., 1996) resembling placebo responses in drug-studies in
major depressive disorder (Walsh et al., 2002). The response
rates between 50% and 76% for remission in the current study
are relatively high compared to those placebo responses to be
interpreted as placebo effects alone, although we cannot rule
out this possibility. Walsh et al. (2002) also show an increasing
trend in placebo responses over time in drug-studies and this
may be the case for possible placebo effects of light treatment
as well.
Due to aging there is a clear reduction of blue light trans-
mission through the lens (Charman, 2003; Giménez et al.,
2010; Van de Kraats and Van Norren, 2007). This might have
consequences for the non-visual effects of short-wavelength
light (Herljevic et al., 2005; Sletten et al., 2009). In the last
two studies, reduced effects of blue light onmelatonin suppres-
sion and alertness in elderly people compared to young people
were observed. In the present study the response percentage
in the “middle age” group was highest and better compared
to the young group, with no significant differences between
the young group and the oldest group. No differences between
the three treatments were found between the age groups,
which may again be explained by either a saturation effect, or
the fact that blue light in particular does not play a huge role
in the light treatment effect of seasonal affective disorder.
It is known that expectations can play a major role in the
treatment of SAD (Levitt and Levitan, 2003). We showed that
expectations for the three different light treatments were not
significantly different, and experience with light treatment
in earlier winter seasons did not play a role in the treatment
effect in the three conditions.
Light is able to induce phase shifts of the biological clock
and it imposes acute effects on melatonin concentration,
body temperature and alertness both during the day and
during the night (Cajochen, 2007; Rüger et al., 2003, 2006).
Since it seems to be especially the short wavelengths that
are responsible for the non-visual effects (Cajochen et al.,
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blue-enriched light on the biological clock and on alertness
would be larger compared to standard white light. Strong
support for an increased response of the biological clock
to blue enriched light is lacking however. A recent study
concluded that bright blue-enriched polychromatic light
is not more effective than standard bright light therapy
for phase advancing or phase delaying circadian rhythms at
light levels about half the intensities we used in the present
study (Smith et al., 2009; Smith and Eastman, 2009). How-
ever, in a working place environment blue-enriched light
(17,000 K) increased levels of alertness and performance
when applied during daytime compared to a standard
white-light condition (4000 K) (Viola et al., 2008). Although
it is difficult to estimate the amount of light reaching the ret-
ina under normal working conditions, the intensities in the
blue spectrum seem to be pretty similar to the intensities
used in Anderson et al. (2009) and Meesters et al. (2011),
and thus much lower then used in the present study. It
is concluded that tests for the superiority of blue enriched
light for treating circadian rhythm sleep disorders or season-
al affective disorder should use low intensities, which if con-
sistently proven to be effective could be an improvement of
the current light therapies in terms of potentially shorter
therapy time, more comfortable light intensities, and lower
energy demands. From the present studies in our group
we conclude that bright and low blue-enriched light is not
better for treating Seasonal Affective Disorder then standard
bright white light treatment. On the other hand shorter
(20 min) daily light exposure and lower intensities
(750 lx) of blue enriched light are as effective as standard
full spectrum light therapy (30 min 10,000 lx), which is an
improvement of the current treatment paradigms. The lack
of a difference between standard full spectrum light and
blue-enriched light does not really favor but definitely not
rule out the hypothesis of the biological clock and/or the
melanopsin photoreceptors being involved in the etiology
of SAD or in the treatment effects of light.
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